Biotechnology company Cell Medica has bought the Cell and Gene Therapy Catapult’s subsidiary, Catapult Therapy TCR.
The subsidiary—which was jointly owned by the Catapult, UCL Business and Imperial Innovations—will continue to develop cancer treatments, Innovate UK announced on 26 June.
Previously, its work had been funded by Innovate UK and had focused on the development of a gene-modified cell therapy, to develop treatments for blood cancers and solid tumours including acute myeloid leukaemia.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.